Method of Generating Multipotent Stem Cells (Patent US12600950B2)
Summary
The USPTO granted Patent US12600950B2 to The Trustees of Columbia University in the City of New York for a method of generating multipotent stem cells. The invention involves delivering reprogramming proteins called Master Regulator (MR) proteins—including BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1—into somatic cells to produce and/or expand multipotent stem cells. The patent application was filed March 31, 2023, and contains 7 claims.
What changed
USPTO granted Patent US12600950B2 to The Trustees of Columbia University in the City of New York. The patent covers a method of generating multipotent stem cells by delivering Master Regulator proteins into somatic cells, including the bromodomain protein BAZ2B identified through bi-species heterokaryon reprogramming experiments. The inventors are Andrea Califano, Maria Pia Cosma, and Karthik Arumugam.
For biotechnology firms, research institutions, and pharmaceutical companies working in stem cell therapies or regenerative medicine, this patent may create licensing requirements or potential freedom-to-operate concerns. Academic researchers in related fields should be aware of the scope of protection granted to Columbia University for Master Regulator-based stem cell reprogramming methods.
What to do next
- Monitor for potential licensing inquiries
- Review patent claims for R&D alignment
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method of generating multipotent stem cells
Grant US12600950B2 Kind: B2 Apr 14, 2026
Assignee
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Inventors
Andrea Califano, Maria Pia Cosma, Karthik Arumugam
Abstract
The method of generating multipotent stem cells is a method for producing and/or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1−/− murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.
CPC Classifications
C12N 5/0647
Filing Date
2023-03-31
Application No.
18194551
Claims
7
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.